FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224917273> ?p ?o ?g. }

• W4224917273 endingPage "45" @default.
• W4224917273 startingPage "38" @default.
• W4224917273 abstract "The prognosis of patients with synchronous metastatic renal cell carcinoma (mRCC) is poor. Whereas single-agent tyrosine kinase inhibition (TKI) is clearly insufficient, the effects can be enhanced by combinations with immune checkpoint inhibitors. Innovative treatment options combining TKI and other immune-stimulating agents could prove beneficial.To evaluate the clinical effects on metastatic disease when two doses of allogeneic monocyte-derived dendritic cells (ilixadencel) are administrated intratumorally followed by nephrectomy and treatment with sunitinib compared with nephrectomy and sunitinib monotherapy, in patients with synchronous mRCC.A randomized (2:1) phase 2 multicenter trial enrolled 88 patients with newly diagnosed mRCC to treatment with the combination ilixadencel/sunitinib (ILIXA/SUN; 58 patients) or sunitinib alone (SUN; 30 patients).The primary endpoints were 18-mo survival rate and overall survival (OS). A secondary endpoint was objective response rate (ORR) assessed up to 18 mo after enrollment. Statistic evaluations included Kaplan-Meier estimates, log-rank tests, Cox regression, and stratified Cochran-Mantel-Haenszel tests.The median OS was 35.6 mo in the ILIXA/SUN arm versus 25.3 mo in the SUN arm (hazard ratio 0.73, 95% confidence interval 0.42-1.27; p = 0.25), while the 18-mo OS rates were 63% and 66% in the ILIXA/SUN and SUN arms, respectively. The confirmed ORR in the ILIXA/SUN arm were 42.2% (19/45), including three patients with complete response, versus 24.0% (six/25) in the SUN arm (p = 0.13) without complete responses. The study was not adequately powered to detect modest differences in survival.The study failed to meet its primary endpoints. However, ilixadencel in combination with sunitinib was associated with a numerically higher, nonsignificant, confirmed response rate, including complete responses, compared with sunitinib monotherapy.We studied the effects of intratumoral vaccination with ilixadencel followed by sunitinib versus sunitinib only in a randomized phase 2 study. The combination treatment showed numerically higher numbers of confirmed responses, suggesting an immunologic effect." @default.
• W4224917273 created "2022-04-28" @default.
• W4224917273 creator A5001812156 @default.
• W4224917273 creator A5006662920 @default.
• W4224917273 creator A5009247683 @default.
• W4224917273 creator A5009523282 @default.
• W4224917273 creator A5017073028 @default.
• W4224917273 creator A5030712482 @default.
• W4224917273 creator A5035036126 @default.
• W4224917273 creator A5046751920 @default.
• W4224917273 creator A5049249562 @default.
• W4224917273 creator A5052385412 @default.
• W4224917273 creator A5057705931 @default.
• W4224917273 creator A5058855375 @default.
• W4224917273 creator A5064442357 @default.
• W4224917273 creator A5067956139 @default.
• W4224917273 creator A5082828068 @default.
• W4224917273 creator A5083328412 @default.
• W4224917273 creator A5084085052 @default.
• W4224917273 creator A5085163402 @default.
• W4224917273 creator A5085773910 @default.
• W4224917273 date "2022-06-01" @default.
• W4224917273 modified "2023-10-15" @default.
• W4224917273 title "Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study" @default.
• W4224917273 cites W1976358776 @default.
• W4224917273 cites W2019607817 @default.
• W4224917273 cites W2129407204 @default.
• W4224917273 cites W2149436029 @default.
• W4224917273 cites W2222086386 @default.
• W4224917273 cites W2324902637 @default.
• W4224917273 cites W2464223050 @default.
• W4224917273 cites W2693271328 @default.
• W4224917273 cites W2767789064 @default.
• W4224917273 cites W2768042048 @default.
• W4224917273 cites W2792937256 @default.
• W4224917273 cites W2805060661 @default.
• W4224917273 cites W2808052158 @default.
• W4224917273 cites W2808165165 @default.
• W4224917273 cites W2904657085 @default.
• W4224917273 cites W2909935405 @default.
• W4224917273 cites W2913745075 @default.
• W4224917273 cites W3004420993 @default.
• W4224917273 cites W3035339338 @default.
• W4224917273 cites W3115827821 @default.
• W4224917273 cites W3131063362 @default.
• W4224917273 cites W3134949580 @default.
• W4224917273 cites W3164361373 @default.
• W4224917273 cites W4210983935 @default.
• W4224917273 doi "https://doi.org/10.1016/j.euros.2022.03.012" @default.
• W4224917273 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35638086" @default.
• W4224917273 hasPublicationYear "2022" @default.
• W4224917273 type Work @default.
• W4224917273 citedByCount "6" @default.
• W4224917273 countsByYear W42249172732020 @default.
• W4224917273 countsByYear W42249172732021 @default.
• W4224917273 countsByYear W42249172732022 @default.
• W4224917273 countsByYear W42249172732023 @default.
• W4224917273 crossrefType "journal-article" @default.
• W4224917273 hasAuthorship W4224917273A5001812156 @default.
• W4224917273 hasAuthorship W4224917273A5006662920 @default.
• W4224917273 hasAuthorship W4224917273A5009247683 @default.
• W4224917273 hasAuthorship W4224917273A5009523282 @default.
• W4224917273 hasAuthorship W4224917273A5017073028 @default.
• W4224917273 hasAuthorship W4224917273A5030712482 @default.
• W4224917273 hasAuthorship W4224917273A5035036126 @default.
• W4224917273 hasAuthorship W4224917273A5046751920 @default.
• W4224917273 hasAuthorship W4224917273A5049249562 @default.
• W4224917273 hasAuthorship W4224917273A5052385412 @default.
• W4224917273 hasAuthorship W4224917273A5057705931 @default.
• W4224917273 hasAuthorship W4224917273A5058855375 @default.
• W4224917273 hasAuthorship W4224917273A5064442357 @default.
• W4224917273 hasAuthorship W4224917273A5067956139 @default.
• W4224917273 hasAuthorship W4224917273A5082828068 @default.
• W4224917273 hasAuthorship W4224917273A5083328412 @default.
• W4224917273 hasAuthorship W4224917273A5084085052 @default.
• W4224917273 hasAuthorship W4224917273A5085163402 @default.
• W4224917273 hasAuthorship W4224917273A5085773910 @default.
• W4224917273 hasBestOaLocation W42249172731 @default.
• W4224917273 hasConcept C126322002 @default.
• W4224917273 hasConcept C126894567 @default.
• W4224917273 hasConcept C143998085 @default.
• W4224917273 hasConcept C168563851 @default.
• W4224917273 hasConcept C203092338 @default.
• W4224917273 hasConcept C207103383 @default.
• W4224917273 hasConcept C2777472916 @default.
• W4224917273 hasConcept C2779490328 @default.
• W4224917273 hasConcept C2780091579 @default.
• W4224917273 hasConcept C2780227381 @default.
• W4224917273 hasConcept C31760486 @default.
• W4224917273 hasConcept C44249647 @default.
• W4224917273 hasConcept C50382708 @default.
• W4224917273 hasConcept C535046627 @default.
• W4224917273 hasConcept C71924100 @default.
• W4224917273 hasConcept C90924648 @default.
• W4224917273 hasConceptScore W4224917273C126322002 @default.
• W4224917273 hasConceptScore W4224917273C126894567 @default.
• W4224917273 hasConceptScore W4224917273C143998085 @default.
• W4224917273 hasConceptScore W4224917273C168563851 @default.

• next